Metabolic Crosstalk in Cancer
Group Leader:
Dr Johan Vande Voorde
Cancer is a multifactorial disease with widespread effects on patients’ health. Cancer cells undergo metabolic rewiring to sustain continued proliferation and to survive in hostile environments. This includes alterations in the uptake and utilization of nutrients and metabolites. As such, the tumour microenvironment is important for metabolite supply to cancer cells and the presence of a tumour affects the normal function of its host organ. In addition, cancer is associated with systemic metabolic changes that can dramatically impact quality of life for patients and their fitness to undergo treatments. Research in our laboratory focuses on metabolic crosstalk between the host and tumours, ultimately aiming to develop new, more efficient therapies.

Lab Reports

Recent Publications

Lab Members
Recent Publications
2025
Goodwin RJA, Marshall JF, Poulogiannis G, Yuneva M, Brindle KM, Takáts Z, Sansom OJ, Bunch J, Barry ST. Visualizing Cancer Heterogeneity at the Molecular and Cellular Levels: Lessons from Rosetta. Cancer Discov. 2025(1):34-38.
Ling S, Dexter A, Race AM, Sharma S, Hamm G, Polanska UM, Marshall JF, Takats Z, Brindle K, Yuneva MO, Poulogiannis G, Campbell AD, Sansom OJ, Goodwin RJA, Bunch J, Barry ST. Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition. Dis Model Mech. 2025;18(2).
Jenkins BJ, Jenkins YR, Ponce-Garcia FM, Moscrop C, Perry IA, Hitchings MD, Uribe AH, Bernuzzi F, Eastham S, Cronin JG, Berisha A, Howell A, Davies J, Blagih J, Williams M, Marsden M, Veale DJ, Davies LC, Niphakis M, Finlay DK, Sinclair LV, Cravatt BF, Hogan AE, Nathan JA, Humphreys IR, Fearon U, Sumpton D, Vande Voorde J, Vale GDD, McDonald JG, Jones GW, Pearson JA, Vincent EE, Jones N. Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function. Nat Commun. 2025;16(1):9484.
Whyte D, Fisher SL, McKenzie CGJ, Sumpton D, Dhayade S, Dornier E, Moore M, Novo D, Peters J, Wiesheu R, Gounis MD, Watt DM, Mackey JBG, McFarlane AJ, Fercoq F, Dehesa Caballero C, Redmond KL, Mitchell LE, Anderson E, Thomson G, Hedley A, Clark W, Leroi S, Dzierozynski LN, Apiz Saab JJ, Lewis CA, Muir A, Halbrook CJ, Strathdee D, Jackstadt R, Nixon C, Dunne P, Carlin LM, Macpherson IR, Roberts EW, Coffelt SB, Blyth K, Sansom OJ, Norman JC, Vande Voorde J, Clarke CJ. Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes. EMBO Rep. 2025.
Najumudeen AK, Vande Voorde J. Spatial metabolomics to unravel cellular metabolism. Nat Rev Genet. 2025.
2024
Jans M, Kolata M, Blancke G, D’Hondt A, Gräf C, Ciers M, Sze M, Thiran A, Petta I, Andries V, Verbandt S, Shokry E, Sumpton D, Vande Voorde J, Berx G, Tejpar S, van Loo G, Iliev ID, Remaut H, Vereecke L. Colibactin-driven colon cancer requires adhesin-mediated epithelial binding. Nature. 2024 Nov;635(8038):472-480.
Peker N, Vande Voorde J. CCL2 as a potential regulator of skeletal muscle wasting in breast cancer. Dis Model Mech. 2024;17(8):dmm052082.
2023
Rattigan KM, Zarou MM, Brabcova Z, Prasad B, Zerbst D, Sarnello D, Kalkman ER, Ianniciello A, Scott MT, Dunn K, Shokry E, Sumpton D, Copland M, Tardito S, Vande Voorde J, Mussai F, Cheng P, Helgason GV. Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Rep. 2023:e56279.
Vande Voorde J, Steven RT, Najumudeen AK, Ford CA, Dexter A, Gonzalez-Fernandez A, Nikula CJ, Xiang Y, Ford L, Maneta Stavrakaki S, Gilroy K, Zeiger LB, Pennel K, Hatthakarnkul P, Elia EA, Nasif A, Murta T, Manoli E, Mason S, Gillespie M, Lannagan TRM, Vlahov N, Ridgway RA, Nixon C, Raven A, Mills M, Athineos D, Kanellos G, Nourse C, Gay DM, Hughes M, Burton A, Yan B, Sellers K, Wu V, De Ridder K, Shokry E, Huerta Uribe A, Clark W, Clark G, Kirschner K, Thienpont B, Li VSW, Maddocks ODK, Barry ST, Goodwin RJA, Kinross J, Edwards J, Yuneva MO, Sumpton D, Takats Z, Campbell AD, Bunch J, Sansom OJ. Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism. 2023.
Villar VH, Allega MF, Deshmukh R, Ackermann T, Nakasone MA, Vande Voorde J, Drake TM, Oetjen J, Bloom A, Nixon C, Müller M, May S, Tan EH, Vereecke L, Jans M, Blancke G, Murphy DJ, Huang DT, Lewis DY, Bird TG, Sansom OJ, Blyth K, Sumpton D, Tardito S. Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology. 2023;19:292-300.
May S, Müller M, Livingstone CR, Skalka GL, Walsh PJ, Nixon C, Hedley A, Shaw R, Clark W, Voorde JV, Officer-Jones L, Ballantyne F, Powley IR, Drake TM, Kiourtis C, Keith A, Rocha AS, Tardito S, Sumpton D, Le Quesne J, Bushell M, Sansom OJ, Bird TG. Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. J Hepatol. 2023;78:1028-1036.
2022
Patel R, Ford CA, Rodgers L, Rushworth LK, Fleming J, Mui E, Zhang T, Watson D, Lynch V, Mackay G, Sumpton D, Sansom OJ, Vande Voorde J, Leung HY. Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Res. 2022;82:2565-2575.
2021
Grosso S, Marini A, Gyuraszova K, Voorde JV, Sfakianos A, Garland GD, Tenor AR, Mordue R, Chernova T, Morone N, Sereno M, Smith CP, Officer L, Farahmand P, Rooney C, Sumpton D, Das M, Teodósio A, Ficken C, Martin MG, Spriggs RV, Sun XM, Bushell M, Sansom OJ, Murphy D, MacFarlane M, Le Quesne JPC, Willis AE. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat Commun. 2021;12:4920.
Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, Nikula CJ, Dexter A, Murta T, Race AM, Sumpton D, Vlahov N, Gay DM, Knight JRP, Jackstadt R, Leach JDG, Ridgway RA, Johnson ER, Nixon C, Hedley A, Gilroy K, Clark W, Malla SB, Dunne PD, Rodriguez-Blanco G, Critchlow SE, Mrowinska A, Malviya G, Solovyev D, Brown G, Lewis DY, Mackay GM, Strathdee D, Tardito S, Gottlieb E, CRUK Rosetta Grand Challenge Consortium, Takats Z, Barry ST, Goodwin RJA, Bunch J, Bushell M, Campbell AD, Sansom OJ. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53(1):16-26.
2020
Casciano JC, Perry C, Cohen-Nowak AJ, Miller KD, Vande Voorde J, Zhang Q, Chalmers S, Sandison ME, Liu Q, Hedley A, McBryan T, Tang HY, Gorman N, Beer T, Speicher DW, Adams PD, Liu X, Schlegel R, McCarron JG, Wakelam MJO, Gottlieb E, Kossenkov AV, Schug ZT. MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer. Br J Cancer. 2020 Mar;122(6):868-884.
2019
Vande Voorde J, Ackermann T, Pfetzer N, Sumpton D, Mackay G, Kalna G, Nixon C, Blyth K, Gottlieb E, Tardito S. Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Science Advances 2019;5:eaau7314.
Clinical Research Fellow
Kyrillus Shohdy*
Postdoctoral Scientist
Federico Bernuzzi*
Postdoctoral Scientist
Lauren Evans*
Postdoctoral Scientist
Nesibe Peker*
Technician
Shannen Leroi*
PhD Student
Atharv Kapoor*
PhD Student
Javier Alias*
PhD Student
Michael Jacques
I’m Michael Jacques, a PhD student in the Ahmad and Vande Voorde labs working on understanding the link between obesity and prostate cancer, and exploring potential therapeutic strategies for managing both simultaneously. I completed my undergraduate degree in Pharmacology at the University of Leeds, including an industrial placement year at AstraZeneca. Outside of the lab, I enjoy football, the gym, walking and travelling.


